tradingkey.logo
tradingkey.logo
Search

Immuneering Announces Overall Survival of First-Line Pancreatic Cancer Patients Treated With Atebimetinib + mGnP

ReutersSep 24, 2025 10:21 PM
facebooktwitterlinkedin
View all comments0

- Immuneering Corp IMRX.O:

  • IMMUNEERING ANNOUNCES EXTRAORDINARY 86% OVERALL SURVIVAL AT 9 MONTHS IN FIRST-LINE PANCREATIC CANCER PATIENTS TREATED WITH ATEBIMETINIB + MGNP

  • IMMUNEERING CORP - ATEBIMETINIB + MGNP SHOWS 53% PFS AT 9 MONTHS IN PANCREATIC CANCER

  • IMMUNEERING CORP - EXPECTS REGULATORY FEEDBACK ON PIVOTAL TRIAL PLANS IN Q4 2025

  • IMMUNEERING CORP - TO INITIATE PIVOTAL TRIAL BY END OF 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI